Cenobamate Treatment of Children with Refractory Epilepsy: The UCLA Experience
Abstract number :
1.412
Submission category :
7. Anti-seizure Medications / 7C. Cohort Studies
Year :
2024
Submission ID :
1339
Source :
www.aesnet.org
Presentation date :
12/7/2024 12:00:00 AM
Published date :
Authors :
Presenting Author: Haley Peters, BS – UCLA
Aria Terango, BS – UCLA
Nathan Tabibzadeh, BS – UCLA
Gurpreet Seehra, MD – UCLA Mattel Children's Hospital, David Geffen School of Medicine
Sariha Moyen, MD – UCLA
Hiroki Nariai, MD, PhD, MS – UCLA Mattel Children's Hospital
Rajsekar Rajaraman, MD, MS – UCLA Mattel Children's Hospital
Raman Sankar, MD, PhD – University of California, Los Angeles
Shaun Hussain, MD, MS – UCLA Mattel Children's Hospital, David Geffen School of Medicine
Rationale: In the United States, cenobamate (CBM) is approved for treatment of focal-onset seizures in adults. Given favorable efficacy in clinical trials, our center has often utilized CBM (off-label) for treatment of children, including patients with other forms of epilepsy. In this retrospective report, we describe efficacy and tolerability in our single-center experience.
Methods: Children (< 18y) who were prescribed CBM were identified with a search of the electronic medical record. For all patients with at least 3 months follow-up, we collected data on demographics, etiology, seizure-types, epilepsy syndrome classification, prior and concomitant medication, and baseline seizure-frequency. We then recorded CBM dosage, weight, adverse events, and percent change in seizure frequency from baseline at (1) the visit closest to 3 months follow-up, and (2) the most recent follow-up visit.
Anti-seizure Medications